IBDEI1PO ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30315,1,4,0)
 ;;=4^O36.1115
 ;;^UTILITY(U,$J,358.3,30315,2)
 ;;=^5016898
 ;;^UTILITY(U,$J,358.3,30316,0)
 ;;=O36.1120^^178^1916^25
 ;;^UTILITY(U,$J,358.3,30316,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30316,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, second tri, unsp
 ;;^UTILITY(U,$J,358.3,30316,1,4,0)
 ;;=4^O36.1120
 ;;^UTILITY(U,$J,358.3,30316,2)
 ;;=^5016900
 ;;^UTILITY(U,$J,358.3,30317,0)
 ;;=O36.1121^^178^1916^26
 ;;^UTILITY(U,$J,358.3,30317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30317,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, second tri, fetus 1
 ;;^UTILITY(U,$J,358.3,30317,1,4,0)
 ;;=4^O36.1121
 ;;^UTILITY(U,$J,358.3,30317,2)
 ;;=^5016901
 ;;^UTILITY(U,$J,358.3,30318,0)
 ;;=O36.1122^^178^1916^27
 ;;^UTILITY(U,$J,358.3,30318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30318,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, second tri, fetus 2
 ;;^UTILITY(U,$J,358.3,30318,1,4,0)
 ;;=4^O36.1122
 ;;^UTILITY(U,$J,358.3,30318,2)
 ;;=^5016902
 ;;^UTILITY(U,$J,358.3,30319,0)
 ;;=O36.1123^^178^1916^28
 ;;^UTILITY(U,$J,358.3,30319,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30319,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, second tri, fetus 3
 ;;^UTILITY(U,$J,358.3,30319,1,4,0)
 ;;=4^O36.1123
 ;;^UTILITY(U,$J,358.3,30319,2)
 ;;=^5016903
 ;;^UTILITY(U,$J,358.3,30320,0)
 ;;=O36.1124^^178^1916^29
 ;;^UTILITY(U,$J,358.3,30320,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30320,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, second tri, fetus 4
 ;;^UTILITY(U,$J,358.3,30320,1,4,0)
 ;;=4^O36.1124
 ;;^UTILITY(U,$J,358.3,30320,2)
 ;;=^5016904
 ;;^UTILITY(U,$J,358.3,30321,0)
 ;;=O36.1125^^178^1916^30
 ;;^UTILITY(U,$J,358.3,30321,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30321,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, second tri, fetus 5
 ;;^UTILITY(U,$J,358.3,30321,1,4,0)
 ;;=4^O36.1125
 ;;^UTILITY(U,$J,358.3,30321,2)
 ;;=^5016905
 ;;^UTILITY(U,$J,358.3,30322,0)
 ;;=O36.1130^^178^1916^31
 ;;^UTILITY(U,$J,358.3,30322,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30322,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, third tri, unsp
 ;;^UTILITY(U,$J,358.3,30322,1,4,0)
 ;;=4^O36.1130
 ;;^UTILITY(U,$J,358.3,30322,2)
 ;;=^5016907
 ;;^UTILITY(U,$J,358.3,30323,0)
 ;;=O36.1131^^178^1916^32
 ;;^UTILITY(U,$J,358.3,30323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30323,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, third tri, fetus 1
 ;;^UTILITY(U,$J,358.3,30323,1,4,0)
 ;;=4^O36.1131
 ;;^UTILITY(U,$J,358.3,30323,2)
 ;;=^5016908
 ;;^UTILITY(U,$J,358.3,30324,0)
 ;;=O36.1132^^178^1916^33
 ;;^UTILITY(U,$J,358.3,30324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30324,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, third tri, fetus 2
 ;;^UTILITY(U,$J,358.3,30324,1,4,0)
 ;;=4^O36.1132
 ;;^UTILITY(U,$J,358.3,30324,2)
 ;;=^5016909
 ;;^UTILITY(U,$J,358.3,30325,0)
 ;;=O36.1133^^178^1916^34
 ;;^UTILITY(U,$J,358.3,30325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30325,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, third tri, fetus 3
 ;;^UTILITY(U,$J,358.3,30325,1,4,0)
 ;;=4^O36.1133
 ;;^UTILITY(U,$J,358.3,30325,2)
 ;;=^5016910
 ;;^UTILITY(U,$J,358.3,30326,0)
 ;;=O36.1134^^178^1916^35
 ;;^UTILITY(U,$J,358.3,30326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30326,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization, third tri, fetus 4
 ;;^UTILITY(U,$J,358.3,30326,1,4,0)
 ;;=4^O36.1134
 ;;^UTILITY(U,$J,358.3,30326,2)
 ;;=^5016911
 ;;^UTILITY(U,$J,358.3,30327,0)
 ;;=O36.1135^^178^1916^36
 ;;^UTILITY(U,$J,358.3,30327,1,0)
 ;;=^358.31IA^4^2
 ;;
 ;;$END ROU IBDEI1PO
